José M Garcia1, John Friend, Suzan Allen. 1. Division of Endocrinology, Diabetes and Metabolism, Baylor College of Medicine, Houston, TX, USA. Jgarcia1@bcm.edu
Abstract
PURPOSE: Cachexia in cancer adversely affects patients' perception of symptoms, well-being, and response to therapy, and shortens survival. Anamorelin, an oral mimetic of ghrelin, has been shown to increase body weight and anabolic hormone levels in healthy volunteers and is being investigated to treat cancer cachexia. METHODS: This multicenter, double-blind, placebo-controlled, crossover study evaluated the effects of anamorelin in 16 patients with different cancers and cachexia. Patients were randomly assigned to anamorelin 50 mg/day or placebo for 3 days. A 3- to 7-day washout period followed and then treatments were switched. Assessments included body weight, appetite, food intake, growth hormone (GH) levels, patient-reported symptom assessments (e.g., the Anderson Symptom Assessment Scale [ASAS] and also an inclusion criterion), and safety. RESULTS:Anamorelin significantly increased body weight compared with placebo (0.77 kg vs. -0.33 kg). Food intake increased compared with placebo, but not significantly. GH significantly increased at all time points (0.5-4 h postdose). Insulin-like growth factor-1 (IGF-1) significantly increased by 54.09 ng/mL with anamorelin treatment compared with -3.56 ng/mL for placebo; significant changes in insulin-like growth factor-binding protein 3 (IGFBP-3) were 0.75 μg/mL vs. -0.19 μg/mL, respectively. Patient-reported symptoms, including appetite as measured by ASAS, significantly improved with anamorelin (8.1 vs. 1.0 for placebo). Adverse events (AEs) in four patients were possibly or probably related to anamorelin: hyperglycemia (two patients), nausea (one patient), and dizziness (one patient). Most AEs were mild; no patients withdrew due to AEs. CONCLUSIONS:Anamorelin showed significant metabolic, clinical, and patient-rated effects in cancer cachexia. Further studies are warranted.
RCT Entities:
PURPOSE:Cachexia in cancer adversely affects patients' perception of symptoms, well-being, and response to therapy, and shortens survival. Anamorelin, an oral mimetic of ghrelin, has been shown to increase body weight and anabolic hormone levels in healthy volunteers and is being investigated to treat cancer cachexia. METHODS: This multicenter, double-blind, placebo-controlled, crossover study evaluated the effects of anamorelin in 16 patients with different cancers and cachexia. Patients were randomly assigned to anamorelin 50 mg/day or placebo for 3 days. A 3- to 7-day washout period followed and then treatments were switched. Assessments included body weight, appetite, food intake, growth hormone (GH) levels, patient-reported symptom assessments (e.g., the Anderson Symptom Assessment Scale [ASAS] and also an inclusion criterion), and safety. RESULTS:Anamorelin significantly increased body weight compared with placebo (0.77 kg vs. -0.33 kg). Food intake increased compared with placebo, but not significantly. GH significantly increased at all time points (0.5-4 h postdose). Insulin-like growth factor-1 (IGF-1) significantly increased by 54.09 ng/mL with anamorelin treatment compared with -3.56 ng/mL for placebo; significant changes in insulin-like growth factor-binding protein 3 (IGFBP-3) were 0.75 μg/mL vs. -0.19 μg/mL, respectively. Patient-reported symptoms, including appetite as measured by ASAS, significantly improved with anamorelin (8.1 vs. 1.0 for placebo). Adverse events (AEs) in four patients were possibly or probably related to anamorelin: hyperglycemia (two patients), nausea (one patient), and dizziness (one patient). Most AEs were mild; no patients withdrew due to AEs. CONCLUSIONS:Anamorelin showed significant metabolic, clinical, and patient-rated effects in cancer cachexia. Further studies are warranted.
Authors: Josè M Garcia; Mariana Garcia-Touza; Rabih A Hijazi; George Taffet; Daniel Epner; Douglas Mann; Roy G Smith; Glenn R Cunningham; Marco Marcelli Journal: J Clin Endocrinol Metab Date: 2005-02-15 Impact factor: 5.958
Authors: Marita Fouladiun; Ulla Körner; Ingvar Bosaeus; Peter Daneryd; Anders Hyltander; Kent G Lundholm Journal: Cancer Date: 2005-05-15 Impact factor: 6.860
Authors: Mari-Anne Rowlands; David Gunnell; Ross Harris; Lars J Vatten; Jeff M P Holly; Richard M Martin Journal: Int J Cancer Date: 2009-05-15 Impact factor: 7.396
Authors: Ralf Nass; Suzan S Pezzoli; Mary Clancy Oliveri; James T Patrie; Frank E Harrell; Jody L Clasey; Steven B Heymsfield; Mark A Bach; Mary Lee Vance; Michael O Thorner Journal: Ann Intern Med Date: 2008-11-04 Impact factor: 25.391
Authors: W D Dewys; C Begg; P T Lavin; P R Band; J M Bennett; J R Bertino; M H Cohen; H O Douglass; P F Engstrom; E Z Ezdinli; J Horton; G J Johnson; C G Moertel; M M Oken; C Perlia; C Rosenbaum; M N Silverstein; R T Skeel; R W Sponzo; D C Tormey Journal: Am J Med Date: 1980-10 Impact factor: 4.965
Authors: F Strasser; T A Lutz; M T Maeder; B Thuerlimann; D Bueche; M Tschöp; K Kaufmann; B Holst; M Brändle; R von Moos; R Demmer; T Cerny Journal: Br J Cancer Date: 2008-01-08 Impact factor: 7.640
Authors: John B Furness; Leni R Rivera; Hyun-Jung Cho; David M Bravo; Brid Callaghan Journal: Nat Rev Gastroenterol Hepatol Date: 2013-09-24 Impact factor: 46.802